Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEORX(nerx) -- Ignore unavailable to you. Want to Upgrade?

To: OldAIMGuy who wrote (561)	1/10/2000 2:19:00 PM
From: Anonymous	Read Replies (1) \| Respond to of 661

FOR THE THREAD - Who is buying today?.....and why?

To: OldAIMGuy who wrote (561)	1/13/2000 7:37:00 PM
From: Ron	Read Replies (2) \| Respond to of 661

Progress...research update today: NERX NeoRx Corporation today announced that its Skeletal Targeted Radiotherapy (STR) product has demonstrated an excellent safety profile at the highest doses in the Phase I portion of its study, supporting the Company's intention to use that dose in the Phase III trial scheduled to begin this year. Efficacy data on these patients will be available later in the year once the patient responses have been evaluated. The Company also reported that it is close to completing the Phase II portion of its trial in which 14 patients were treated at the highest STR doses. NeoRx reported that 12 of 27 multiple myeloma patients evaluated for response had achieved complete remission of their cancers, and that these patients had been treated at lower doses. "Even at the highest doses of STR, multiple myeloma patients exhibited no significant side effects," said Robert Caspari, MD, NeoRx's Vice President of Medical and Regulatory Affairs. "This is especially gratifying because it enables us to deliver high radiation doses to the site of a tumor without the patient experiencing toxicity beyond that believed caused by the co-administered chemotherapy, opening prospects for treating older patients with intensive and effective treatments and expanding the potential indications to other diseases such as prostate cancer. We intend to meet with the FDA this quarter to agree on the final design of the Phase III study." STR is a drug that delivers a unique radionuclide, holmium-166, to bone and that accumulates preferentially around cancers in the bone. No binding to other organs has been observed in preclinical or clinical studies, and the portion that is not bound to bone is rapidly excreted in the urine. It is this distribution in the body and rapid clearance that is believed to result in the high doses to the tumor and excellent safety profile. STR is, therefore, potentially applicable to treating cancers that arise in bone, such as multiple myeloma, leukemia, some lymphomas and primary tumors of bone, and cancers that spread to bone, such as prostate and breast cancer. NeoRx Corporation is developing innovative products designed to provide improved, cost-effective treatments for patients with cancer.